EU joins Avastin breast cancer review; Watchdogs: No evidence of vaccine-narcolepsy link;

 @FiercePharma: EMA pulls Avandia; FDA restricts use. Article | Follow @FiercePharma

> European regulators are reviewing the benefits of using Roche's top-selling Avastin drug in breast cancer, in light of fresh clinical trial results; the review comes as FDA is also reconsidering the indication. Report

> There is no evidence to link GlaxoSmithKline's H1N1 swine flu vaccine Pandemrix to cases of narcolepsy, European regulators said, but a full review is needed and will take three to six months. Report

> Breast cancer rates among postmenopausal women in Canada dropped nearly 10 percent after a 2002 study that found taking hormone replacement therapy could increase cancer risk, researchers said. Report

> Royal DSM is in talks with potential Chinese and Indian partners for its penicillin unit in a bid to boost Asian sales and revive profitability, CEO Feike Sijbesma said in an interview. Report

> Goldman Sachs is very bullish on Mylan even though many investors are skeptical about a stock that has declined by 20 percent in the past six months. Report

> Pharmacists and other health-care practitioners say ongoing drug shortages are accompanied by difficulties including a lack of available information, trouble finding alternative medications, and deadly errors. Report

Biotech News

@FierceBiotech: Third Rock leads $30M round for antibody upstart. Article  | Follow @FierceBiotech

 @JohnCFierce: AstraZenceca/Rigel RA drug (subject of a $1.2B pact) gets promising data in IIb. Item | Follow @JohnCFierce

> AZ, BMS drug dapagliflozin supports weight loss. Story

> EU regulators rebuff Merck KGaA on MS drug. Article

> Alnylam announces 25-30% reduction of workforce. Item

> AZ gets positive opinion for heart drug in EU. News

> FDA accepts CMC plan for lead Bionovo drug. Story

And Finally... The rise in ADHD diagnoses indicates one of two things: either children are more fidgety and less able to focus these days, or parents and doctors are less patient with the squirms and jiggles of childhood. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.